Summary:
United States Patent 6,171,613 (March 13, 2001), titled "Treatment of Alzheimer's disease," encompasses therapeutic methods and compositions targeting beta-amyloid aggregation, a hallmark of Alzheimer’s disease. The patent claims cover specific methods of administering peptide-based agents to inhibit amyloid formation, marketing a novel peptide sequence, and related pharmaceutical compositions. The patent landscape includes a broad array of filings in Alzheimer’s therapeutics, particularly peptide-based agents, chaperones, and aggregation inhibitors, indicating a competitive environment with active innovation in disease-modifying therapies.
What is the scope of Patent 6,171,613?
Claims Overview:
-
Method Claims:
The patent primarily claims methods for treating Alzheimer’s by administering peptides that inhibit beta-amyloid aggregation. These peptides are characterized by specific amino acid sequences that prevent the formation of neurotoxic aggregates.
-
Peptide Composition Claims:
Claims describe particular peptide sequences designed to target beta-amyloid protein. They include various formulations, such as cyclic peptides, fusion peptides, and analogs with modifications that increase stability or bioavailability.
-
Pharmaceutical Formulations:
The patent covers compositions containing these peptides, potentially combined with carriers or adjuvants for enhanced delivery.
-
Inhibition of Amyloid Pathology:
The core claim is the use of these agents to reduce amyloid plaque formation, thereby ameliorating Alzheimer’s pathology.
Key Claims Specifics:
| Claim Type |
Description |
| Method of Treatment |
Administering peptides that interfere with amyloid aggregation |
| Peptide Structure |
Specific sequences, e.g., targeting amino acids 17-24 or 35-42 of beta-amyloid |
| Composition Claims |
Pharmaceutical compositions with peptides, adjuvants, or carriers |
| Analog Claims |
Variations of peptide sequences that maintain anti-aggregation activity |
Claim Limitations and Scope:
- Narrower claims focus on specific peptide sequences and modifications.
- Broader claims encompass any peptide capable of inhibiting beta-amyloid aggregation with predictable use in Alzheimer’s treatment.
- The scope is limited to peptides and formulations as described, not encompassing unrelated therapeutic modalities.
What does the patent landscape look like for this technology?
Major Developers and Patent Entries:
- Several research institutions and pharmaceutical companies have filed patents on amyloid-targeting peptides and other disease-modifying strategies, including Eli Lilly, Pfizer, and academic entities.
- Similar patents cover different peptide sequences, conjugates, or delivery systems, indicating intense research activity.
- Patent filings date as early as the late 1990s, with continuations and new filings related to peptide stability, delivery (e.g., crossing the blood-brain barrier), and modified peptides.
Competitive Patent Classes:
| Patent Class |
Description |
| 514/348 |
Peptide drugs for neurological conditions |
| 514/350 |
Anti-aggregation agents targeting beta-amyloid |
| 514/351 |
Peptide analogs with enhanced stability or delivery features |
Patent Trends (Pre- and Post-2001):
- Post-2001 filings include peptides with modified amino acids, formulations for intranasal or systemic delivery, and combination therapies.
- Several patents expand claims to include small molecules that inhibit amyloid aggregation, overlapping with peptide initiatives.
Relevant Patent Filings & R&D Activity:
| Year |
Filing Number |
Title |
Assignee |
Status |
| 2002 |
US20020028556A1 |
Amyloid aggregation inhibitors |
Eli Lilly |
Pending/Published |
| 2005 |
US20050246236A1 |
Peptide conjugates for Alzheimer’s |
Pfizer |
Pending |
| 2010 |
US7863083B2 |
Peptide stabilization methods |
Academic |
Issued |
Recent activity reflects diversification into nanoparticle delivery and combination therapies, extending the fundamental peptide approach.
What are the key limitations and opportunities?
- The patent scope is primarily peptide-centric; broader disease-modifying strategies might not be covered.
- Peptide stability, blood-brain barrier (BBB) permeability, and immunogenicity remain challenges.
- The landscape suggests ongoing patent filings aim to cover delivery methods, peptide modifications, and combination approaches.
Summary table: Patent Claims and Landscape
| Aspect |
Details |
| Claim Scope |
Peptide sequences, methods of administration, compositions for amyloid inhibition |
| Major Competitors |
Eli Lilly, Pfizer, academic institutions |
| Patent Classes |
514/348, 514/350, 514/351 |
| Recent Trends |
Delivery improvements, peptide modifications, combination therapies |
Key Takeaways
- The 6,171,613 patent primarily claims peptide-based methods for Alzheimer’s treatment targeting beta-amyloid aggregation.
- Its claims are focused on specific sequences and pharmaceutical formulations designed to inhibit amyloid plaque formation.
- The patent landscape exhibits a high level of activity, particularly from pharmaceutical companies and research organizations pursuing peptide, small molecule, and delivery system innovations.
- Opportunities exist in enhancing peptide stability, BBB permeability, and combination therapies beyond the scope of existing patents.
- The strategic importance for companies lies in differentiation through delivery methods, peptide modifications, and expanding indications.
FAQs
1. How broad are the claims of Patent 6,171,613?
The claims cover specific peptide sequences and their use in inhibiting beta-amyloid aggregation, with some broader claims encompassing any peptide capable of such activity. The scope does not include unrelated classes of Alzheimer’s therapeutics.
2. Can this patent be challenged or circumvented?
Yes. Given the specificity of peptide sequences, competitors can explore alternative sequences, small molecule inhibitors, or different delivery methods to avoid infringement.
3. What are the main patent challenges for peptide therapeutics targeting Alzheimer’s?
Stability, delivery across the BBB, immunogenicity, and patenting peptide sequences that are sufficiently broad to prevent design-around challenges.
4. How does the patent landscape influence R&D in Alzheimer’s?
High activity in peptide-based therapies indicates ongoing innovation, but also tight patent thickets requiring careful freedom-to-operate analysis.
5. Is this patent still enforceable?
Likely, as it was issued in 2001 with a standard patent term of 20 years from filing, potentially expiring around 2021-2023, depending on filings and extensions.
References:
[1] U.S. Patent No. 6,171,613.
